{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-115533","form_type":"8-K","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.419915+00:00","generated_at":"2026-05-22T03:58:46.943596+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silence Therapeutics Q1 net loss widens to $28.5M; cash runway extended into 2028","bullets":["Cash and short-term investments $136.5M at Mar 31, 2025, down from $147.3M at Dec 31, 2024.","Net loss $28.5M ($0.20/ADS) vs $2.3M ($0.02) in Q1 2024; R&D up $9.0M to $20.8M.","Divesiran Phase 2 SANRECO enrollment on track to complete by year-end 2025; EHA presentation June 12-15.","Cost savings initiatives implemented to extend cash guidance into 2028; Phase 3 readiness for zerlasiran ongoing.","Appointed Tim McInerney to Board of Directors effective May 5, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-115533","json":"https://secwatch.observer/filing/0001193125-25-115533.json","markdown":"https://secwatch.observer/filing/0001193125-25-115533.md","text":"https://secwatch.observer/filing/0001193125-25-115533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525115533/0001193125-25-115533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525115533/d932196d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:58:46.943596+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}